Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup
Aurore Touzart, Anand Mayakonda, Charlotte Smith, Joschka Hey, Réka Tóth, Agata Cieślak, Guillaume P. Andrieu, Christine Tran Quang, Mehdi Latiri, Jacques Ghysdael, Salvatore Spicuglia, Hervé Dombret, Norbert Ifrah, Elizabeth Macintyre, Pavlo Lutsik, Nicolas Boissel, Christoph Plass, Vahid Asnafi
Abstract
) delayed tumor progression. These findings suggest that epigenetic-based therapies may provide an alternative treatment option in hypermethylated T-ALL.
Topics & Concepts
DNA methylationEpigeneticsHypomethylating agentCancer researchDecitabineBiologyIsocitrate dehydrogenaseHomeoboxMethylationAzacitidineLeukemiaTranscription factorMolecular biologyImmunologyGeneticsGeneGene expressionBiochemistryEnzymeAcute Lymphoblastic Leukemia researchEpigenetics and DNA MethylationChildhood Cancer Survivors' Quality of Life